Format

Send to

Choose Destination
AJR Am J Roentgenol. 2019 Apr 30:1-8. doi: 10.2214/AJR.18.20699. [Epub ahead of print]

Single-Center Prospective Evaluation of 68Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer.

Author information

1
1 Department of Radiology and Biomedical Imaging, University of California San Francisco, 505 Parnassus Ave, M-391, San Francisco, CA 94143-0628.
2
2 Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, CA.
3
3 Division of Nuclear Medicine, Stanford University Medical Center, Palo Alto, CA.
4
4 Department of Urology, University of California San Francisco, San Francisco, CA.
5
5 Department of Radiation Oncology, University of California San Francisco, San Francisco, CA.
6
6 Department of Radiology, San Francisco VA Medical Center, San Francisco, CA.

Abstract

OBJECTIVE. The purpose of this study was to determine the diagnostic accuracy of 68Ga-labeled prostate-specific membrane antigen 11 (PSMA-11) PET for disease detection in patients with prostate cancer who have biochemically recurrent disease after radiation therapy or prostatectomy. SUBJECTS AND METHODS. One hundred fifty patients underwent 68Ga-PSMA-11 PET/CT or PET/MRI, and the images were interpreted by two blinded board-certified radiologists. Each reader evaluated for the presence or absence of PSMA-positive disease within the prostate bed, pelvic lymph nodes, bones, and soft tissues (extrapelvic lymph nodes and visceral structures). The presence or absence of disease was confirmed by histopathologic analysis if available. For patients who did not have pathologic analysis, a composite of imaging and clinical follow-up was used as the reference standard. RESULTS. The median prostate-specific antigen level was 2.1 ng/mL. Forty-three patients had pathologic correlation, and for 29 patients a composite of imaging and follow-up was used to determine the presence or absence of disease. With substantial to almost perfect interreader reliability by region (κ = 0.78-0.87), 68Ga-PSMA-11 PET had high sensitivity per region (up to 100%) and per patient (up to 89.8%). It also had high positive predictive value per region (up to 100%) and per patient (up to 91.5%). Sensitivity was highest for bone metastases and lowest for soft-tissue metastases. Positive predictive value was highest for bone metastases and lowest for prostate bed recurrence. CONCLUSION. Gallium-68-labeled PSMA-11 PET is sensitive for prostate cancer metastases in patients with biochemically recurrent prostate cancer. It has high positive predictive value and substantial to almost perfect interrater reliability.

KEYWORDS:

PET/CT; PET/MRI; PMSA; prostate cancer; prostate-specific membrane antigen

PMID:
31039025
DOI:
10.2214/AJR.18.20699

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center